Home
PBM
PBM News

Latest PSYENCE BIOMEDICAL LTD (PBM) News on December 18, 2024

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

GlobeNewswire

a day ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical executes binding agreements with Optimi Health

TipRanks

7 days ago

Psyence Biomedical executes binding agreements with Optimi Health

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

GlobeNewswire

8 days ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

GlobeNewswire

12 days ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

GlobeNewswire

15 days ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Market Exclusive

24 days ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

GlobeNewswire

a month ago

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

GlobeNewswire

a month ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

GlobeNewswire

a month ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

GlobeNewswire

2 months ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

GlobeNewswire

2 months ago

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire

2 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire

2 months ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

GlobeNewswire

2 months ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

GlobeNewswire

2 months ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

GlobeNewswire

2 months ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

GlobeNewswire

3 months ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

GlobeNewswire

3 months ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire

3 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire

3 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire

3 months ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

GlobeNewswire

3 months ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire

3 months ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

GlobeNewswire

3 months ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

GlobeNewswire

3 months ago

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

GlobeNewswire

4 months ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

GlobeNewswire

4 months ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Newsfile

4 months ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

GlobeNewswire

4 months ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

GlobeNewswire

5 months ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire

5 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire

5 months ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

US home sales dip, Secret Service director resigns: Catalysts

Yahoo Finance Video

5 months ago

US home sales dip, Secret Service director resigns: Catalysts

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire

5 months ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

GlobeNewswire

7 months ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

GlobeNewswire

8 months ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire

8 months ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire

8 months ago

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

GlobeNewswire

9 months ago

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

GlobeNewswire

9 months ago

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

GlobeNewswire

9 months ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

GlobeNewswire

9 months ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

GlobeNewswire

9 months ago

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

GlobeNewswire

9 months ago

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

GlobeNewswire

9 months ago

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Trump vs. Biden: How the 2024 election could affect Exxon, Nvidia, and other stocks

Yahoo Finance

a year ago

Trump vs. Biden: How the 2024 election could affect Exxon, Nvidia, and other stocks

Girona take Liga lead back with win at Celta

AFP

a year ago

Girona take Liga lead back with win at Celta

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.

Motley Fool

a year ago

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.

Whether or not the Fed cuts rates is not the right question

Yahoo Finance

a year ago

Whether or not the Fed cuts rates is not the right question

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

Motley Fool

a year ago

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

The S&P 500 Just Hit an All-Time High. Here's 1 Artificial Intelligence (AI) Stock to Buy and Hold Hand Over Fist.

Motley Fool

a year ago

The S&P 500 Just Hit an All-Time High. Here's 1 Artificial Intelligence (AI) Stock to Buy and Hold Hand Over Fist.

Springfield News-Sun, Ohio

a year ago

Local region economic outlook is strong for 2024

Dynagas LNG Partners LP Declares Cash Distribution on Its Series A Preferred units

GlobeNewswire

a year ago

Dynagas LNG Partners LP Declares Cash Distribution on Its Series A Preferred units

Sono-Tek Reports 59% Increase in Q3 Fiscal 2024 Net Sales to Record $5.7 Million and Provides Sales Guidance for Fiscal Year 2024

GlobeNewswire

a year ago

Sono-Tek Reports 59% Increase in Q3 Fiscal 2024 Net Sales to Record $5.7 Million and Provides Sales Guidance for Fiscal Year 2024

GlobeNewswire

a year ago

QuantaSing Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

Vroom Announces "At The Market" (ATM) Equity Offering Program

Business Wire

a year ago

Vroom Announces "At The Market" (ATM) Equity Offering Program

AVITA Medical Updates Full Year 2023 Guidance

GlobeNewswire

a year ago

AVITA Medical Updates Full Year 2023 Guidance

Skillsoft Research Reveals Organizations Struggling to Balance CSR Core Values With External Pressures

Business Wire

a year ago

Skillsoft Research Reveals Organizations Struggling to Balance CSR Core Values With External Pressures

Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2024

PR Newswire

a year ago

Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2024

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

Thomson Reuters StreetEvents

a year ago

Q3 2023 Xtant Medical Holdings Inc Earnings Call

Xtant Medical to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Xtant Medical to Participate in Upcoming Investor Conferences

Innovative Food Holdings, Inc. Reports Financial Results for Third Quarter of 2023

GlobeNewswire

a year ago

Innovative Food Holdings, Inc. Reports Financial Results for Third Quarter of 2023

Share on Social Networks: